Annual report pursuant to Section 13 and 15(d)

Segment Information

v3.24.1
Segment Information
12 Months Ended
Dec. 31, 2023
Segment Information  
Segment Information

18. Segment Information

The Company operates in two reportable segments, Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development. The accounting policies of the Company’s segments are the same as those described in Note 2. The following tables summarize, for the periods indicated, operating results from continued operations by reportable segment:

Pharmaceutical

    

and

Dermatology

Biotechnology

Products

Product

Year Ended December 31, 2023

    

Sales

    

Development

    

Consolidated

Net revenue

$

79,181

$

5,332

$

84,513

Cost of goods - product revenue

 

(26,660)

 

 

(26,660)

Research and development

 

(7,541)

 

(98,530)

 

(106,071)

Selling, general and administrative

(47,053)

(47,071)

(94,124)

Other expense

 

(1,559)

 

(9,732)

 

(11,291)

Income tax expense

(221)

(300)

(521)

Segment loss

$

(3,853)

$

(150,301)

$

(154,154)

Pharmaceutical

and

Dermatology

Biotechnology

Products

Product

Year Ended December 31, 2022

    

Sales

    

Development

    

Consolidated

Net revenue

$

73,669

$

2,074

$

75,743

Cost of goods - product revenue

 

(30,775)

 

 

(30,775)

Research and development

 

(10,943)

 

(123,933)

 

(134,876)

Selling, general and administrative

 

(59,503)

(54,153)

(113,656)

Other expense

(2,048)

 

(7,852)

 

(9,900)

Income tax (expense) benefit

(449)

(449)

Segment loss

$

(29,600)

$

(184,313)

$

(213,913)

The following tables summarize, for the periods indicated, total assets by reportable segment:

Pharmaceutical

    

and

($ in thousands)

Dermatology

Biotechnology

Products

Product

December 31, 2023

    

Sales

    

Development

    

Total Assets

Intangible assets, net

$

20,287

$

$

20,287

Tangible assets

56,561

90,678

147,239

Total segment assets

$

76,848

$

90,678

$

167,526

Pharmaceutical

    

and

($ in thousands)

Dermatology

Biotechnology

Products

Product

December 31, 2022

    

Sales

    

Development

    

Total Assets

Intangible assets, net

$

27,197

$

$

27,197

Tangible assets

77,964

189,140

267,104

Total segment assets

$

105,161

$

189,140

$

294,301